Myriad Genetics Inc
Research Myriad Genetics Inc (MYGN) on Bullrun: market cap USD 401.52M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMYGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 401.52M
- Financial periodQ2 2026
- RevenueUSD 190.70M
- Net income-USD 43.20M
- Free cash flow-USD 11.50M
- Gross margin66.6%
Valuation Snapshot
latest market cap is USD 401.52M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 824.50M | -USD 366.00M | -USD 25.60M | 69.9% | -3.95 | USD 149.60M | USD 119.90M | USD 368.00M |
| FY2024 | USD 837.60M | -USD 127.00M | -USD 38.40M | 69.9% | -1.41 | USD 102.40M | USD 39.60M | USD 701.10M |
| FY2023 | USD 753.20M | -USD 263.00M | -USD 184.20M | 68.6% | -3.18 | USD 132.10M | USD 38.50M | USD 783.20M |
| FY2022 | USD 678.40M | -USD 112.00M | -USD 151.60M | 70.2% | -1.39 | USD 56.90M | USD 0 | USD 885.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 401.52M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 575.03M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.25B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.72B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.18B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.21B | n/a | n/a | n/a |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Myriad Genetics Inc's market cap?
Myriad Genetics Inc's market capitalization is USD 401.52M.
What does Myriad Genetics Inc do?
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.